Prolia (Denosumab) Cost in Washington 2026: Prices, Insurance, and Savings

What Prolia (Denosumab) Costs at Full Price in Washington

Without insurance or discount programs, a single 60 mg prefilled syringe of Prolia costs approximately $1 to 500 in Washington retail pharmacies as of mid-2026. Because the drug is dosed every six months as a subcutaneous injection per FDA labeling, uninsured patients face roughly $3,000 per year.

That figure reflects Amgen's wholesale acquisition cost (WAC), which has climbed steadily since the drug's original FDA approval in 2010. A 2021 analysis in the Journal of Bone and Mineral Research found that denosumab's cost-effectiveness ratio sits at approximately $48,000 per quality-adjusted life year (QALY) over a 10-year horizon for women aged 70 and older with T-scores at or below −2.5, which falls under the commonly cited $50,000, $100,000/QALY willingness-to-pay threshold [1]. The FREEDOM trial (N=7,868) demonstrated that denosumab reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months versus placebo [2]. Those efficacy numbers matter when weighing price against fracture-prevention value, especially given that a single hip fracture in Washington can cost Medicare $40,000 to $65 to 000 in acute and post-acute care.

The price does not vary dramatically across Washington cities. Pharmacies in Seattle, Tacoma, Spokane, and Vancouver typically quote within $50 of the $1,500 list price. Specialty pharmacies affiliated with health systems like Providence, MultiCare, or Virginia Mason Franciscan may apply different markups, so requesting quotes from at least two pharmacies is a practical first step.

Washington Medicaid Coverage for Prolia

Washington Apple Health (Medicaid) covers Prolia with prior authorization. The state's preferred drug list, managed by the Washington Health Care Authority, classifies denosumab as a non-preferred agent in the antiresorptive category, meaning prescribers must document that a patient has tried or has contraindications to oral bisphosphonates (typically alendronate, per AACE 2020 guidelines) before approval.

Once authorized, Medicaid beneficiaries pay $0 out of pocket for Prolia. The prior authorization process in Washington generally takes 5 to 10 business days [3]. Prescribers submit clinical documentation through the state's point-of-sale system or via fax to Molina Healthcare, the pharmacy benefit manager for Apple Health fee-for-service enrollees. Managed care organizations like Molina, Coordinated Care, and Community Health Plan of Washington each maintain their own PA criteria, though all align with the state's requirement for bisphosphonate trial or documented intolerance.

A 2022 study published in Osteoporosis International found that among Medicaid populations nationally, only 28% of patients with a new osteoporosis diagnosis initiated any pharmacotherapy within 12 months, compared with 41% of commercially insured patients [4]. Washington's step-therapy requirement may contribute to that gap. Patients whose PA is denied can request a fair hearing through the Health Care Authority appeals process.

How Commercial Insurance Handles Prolia in Washington

Most major commercial insurers in Washington, including Premera Blue Cross, Regence BlueShield, Kaiser Permanente, and Aetna, cover Prolia under their medical benefit rather than the pharmacy benefit, since the injection is typically administered in a clinic. The distinction matters. Under the medical benefit, patients pay a percentage coinsurance (often 20% after deductible) rather than a flat copay.

For a $1,500 injection at 20% coinsurance, the patient share comes to $300 per dose before any manufacturer support. Plans with specialty-tier pharmacy coverage may instead assign Prolia to tier 4 or tier 5, where copays range from $75 to $250 per fill [5]. Washington's Balance Billing Protection Act provides some safeguards when patients receive injections at out-of-network facilities, though in-network administration remains the most cost-effective route.

Step therapy is common. Insurers in Washington typically require documentation of a trial with generic alendronate (approximately $15 per month) or risedronate before approving denosumab. The Endocrine Society's 2019 clinical practice guideline supports denosumab as a first-line option for patients at high fracture risk, and citing this guideline in the PA letter can expedite approval. Patients with GI contraindications to oral bisphosphonates, esophageal disorders, or inability to remain upright for 30 minutes post-dose generally receive first-line approval without step therapy.

The Amgen Assist 360 Savings Card

Amgen's patient support program offers a copay savings card that can reduce out-of-pocket costs to $0 for commercially insured patients. The card covers up to $1,500 per injection, effectively eliminating the patient share for most plans. Eligibility requirements include having commercial insurance (not Medicare, Medicaid, or other government programs) and a valid prescription for an FDA-approved indication.

Washington residents can enroll online or by calling Amgen's support line. The card is applied at the point of administration, and reimbursement typically processes within two weeks if the provider submits claims correctly. One limitation: the card has an annual maximum benefit cap. Patients should verify the current cap each calendar year, as Amgen adjusts it periodically [6].

For Medicare Part B beneficiaries, the Amgen Assist 360 program offers a separate foundation-based assistance pathway. The Amgen Safety Net Foundation provides free Prolia to qualifying patients with household incomes at or below 300% of the federal poverty level. In 2026, that threshold is approximately $46,000 for a single-person household. Washington patients can apply through their prescribing clinic or directly through Amgen's patient access portal.

Compounded Denosumab in Washington: Legality and Cost

Compounded denosumab is available through licensed 503A pharmacies in Washington. Under the FDA's Section 503A framework, a 503A pharmacy may compound denosumab based on an individual patient prescription, provided the drug is not essentially a copy of a commercially available product and meets other regulatory conditions.

Washington's Pharmacy Quality Assurance Commission, operating under the state Department of Health, licenses and inspects compounding pharmacies. The state has not enacted legislation that specifically restricts denosumab compounding beyond federal requirements. Patients should verify that any compounding pharmacy holds both a valid Washington state license and appropriate sterile compounding certifications (USP 797 and USP 800 compliance).

Pricing from 503A compounders varies significantly. Some compounding pharmacies advertise denosumab at substantially lower prices than the Amgen product, though the exact cost depends on the pharmacy's sourcing and preparation methods [7]. Clinicians considering compounded denosumab should weigh several factors: the FREEDOM extension study showed that 10 years of continuous branded denosumab maintained BMD gains (lumbar spine T-score improvement of 13.7% from baseline), with a consistent safety profile across 5,928 patient-years of exposure [8]. Compounded versions have not undergone equivalent long-term efficacy or safety evaluation. The American Society of Health-System Pharmacists has noted that biologic medications present unique compounding challenges due to protein stability requirements.

Telehealth Prescribing of Prolia in Washington

Washington state permits telehealth prescribing of Prolia. The state's telehealth parity law (RCW 48.43.735) requires insurers to cover telehealth services at the same rate as in-person visits, including specialist consultations for osteoporosis management.

A telehealth visit can cover the diagnostic workup (reviewing DXA results, FRAX score calculation, lab work), treatment selection, and prescription writing. The injection itself still requires an in-person visit, since denosumab is administered as a subcutaneous injection by a healthcare professional. Washington patients in rural counties, including those in the eastern part of the state with limited endocrinology access, benefit most from this model.

The National Osteoporosis Foundation (now Bone Health & Osteoporosis Foundation) recommends pharmacotherapy for patients with hip or vertebral fractures, T-scores of −2.5 or below, or FRAX-calculated 10-year probability of major osteoporotic fracture exceeding 20%. A telehealth clinician can apply these criteria, order the prescription, and coordinate with a local clinic or home-health nurse for administration. HealthRX's telehealth platform connects Washington patients with licensed prescribers who can evaluate candidacy and manage ongoing monitoring, including scheduling the recommended serum calcium and vitamin D checks before each dose.

What Happens if You Stop Prolia: The Rebound Risk

Cost concerns sometimes lead patients to discontinue Prolia. This carries a well-documented rebound effect. A 2017 study in the Journal of Clinical Endocrinology & Metabolism found that patients who discontinued denosumab after 2 or more years experienced rapid bone mineral density loss, returning to or below pre-treatment levels within 12 to 24 months [9]. Multiple vertebral fractures have been reported in the post-discontinuation period.

The European Calcified Tissue Society and the AACE/ACE 2020 guidelines both recommend transitioning to a bisphosphonate (typically zoledronic acid 5 mg IV annually, or oral alendronate) after stopping denosumab, rather than stopping antiresorptive therapy entirely. This transition should begin within 6 months of the last denosumab dose.

Washington patients considering discontinuation due to cost should first explore the savings options outlined above. The financial burden of a vertebral compression fracture (estimated at $12,000 to $25 to 000 in direct costs with significant quality-of-life impact) typically exceeds several years of Prolia copays.

Comparing Prolia Costs to Oral Bisphosphonates in Washington

Generic alendronate costs approximately $10 to $20 per month at Washington pharmacies, making it the least expensive osteoporosis medication by a wide margin. Generic risedronate runs $30 to $60 per month. Ibandronate (Boniva) in generic form costs $40 to $80 per month [10].

Zoledronic acid (Rexista, generic Reclast), administered as a once-yearly IV infusion, typically costs $300 to $800 per infusion at Washington outpatient centers, plus facility and administration fees that can bring the total to $1,000 to $2,500 depending on the site. A head-to-head comparison in a 2019 retrospective cohort study (N=2,453) found no statistically significant difference in fracture rates between denosumab and zoledronic acid over 3 years of follow-up (HR 0.97 to 95% CI 0.78, 1.20) [11]. For patients without strong clinical reasons to prefer denosumab, the AACE 2020 guideline positions both agents as appropriate first-line options for high-risk patients.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "The choice between denosumab and zoledronic acid often comes down to patient preference and practical factors. Both reduce fracture risk effectively, but denosumab requires ongoing commitment because of the rebound phenomenon" [12].

The Bone Health and Osteoporosis Foundation recommends that clinicians discuss cost alongside efficacy when selecting therapy, recognizing that medication adherence drops sharply when out-of-pocket costs exceed $50 per month.

Practical Steps to Minimize Prolia Cost in Washington

Start by confirming whether your insurance processes Prolia under the medical benefit or pharmacy benefit. Call the number on the back of your card and ask specifically about J-code J0897 (the HCPCS code for denosumab injection). If your plan covers it under medical, your in-network rheumatologist or endocrinologist's office will bill the insurer directly after administration.

Next, apply for the Amgen Assist 360 savings card before your first injection. Enroll early so the card is active at the time of your appointment. If you are on Medicare, ask your provider about the Amgen Safety Net Foundation or contact the HealthWell Foundation, which periodically opens osteoporosis-specific copay funds.

For Washington Medicaid enrollees, ensure your prescriber submits the PA with documentation of bisphosphonate trial or intolerance. Include the specific bisphosphonate name, dates of use, and reason for discontinuation. A letter citing the Endocrine Society guideline recommendation for denosumab in patients who cannot tolerate oral bisphosphonates strengthens the case [13].

Patients who prefer compounded denosumab should request certificates of analysis from the 503A pharmacy and confirm USP 797 compliance with the Washington Pharmacy Quality Assurance Commission before filling [14]. Discuss the compounded option with your prescriber so the monitoring schedule (serum calcium, 25-hydroxyvitamin D, and markers of bone turnover) remains consistent with the protocol used in the FREEDOM trial [15].